知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1157 条记录 (耗时 0.034 秒)

    Injection device having automatic needle retraction
    115.
    发明授权
    Injection device having automatic needle retraction 有权

    公开(公告)号：US10232121B2

    公开(公告)日：2019-03-19

    申请号：US15126666

    申请日：2015-03-16

    申请人： Novo Nordisk A/S

    发明人： Henrik Bengtsson ,  Ronan Carroll

    IPC分类号： A61M5/31 ,  A61M5/315 ,  A61M5/32 ,  A61M5/24 ,  A61M5/20

    摘要： The present invention relates to an injection device for delivering set doses of a liquid drug to a user. The injection device has a scale drum for displaying the set dose, which scale drum is helically guided in a housing. The scale drum is thus rotational in relation to the housing between a zero position and a set position for displaying the set dose. Further, a needle cannula secured to a hub is mounted in an axially movable manner. The axial movement of the hub is generated by a spring. A blocking mechanism interacting between the scale drum and hub controls the axial movement of the hub such that the needle cannula automatically retracts from the skin of a user in response to the scale drum reaching the zero position.

    Accessory device with mounting safety feature
    117.
    发明授权
    Accessory device with mounting safety feature 有权

    公开(公告)号：US10213554B2

    公开(公告)日：2019-02-26

    申请号：US15551727

    申请日：2016-02-25

    申请人： Novo Nordisk A/S

    发明人： Jens Christian Andersen ,  Preben Mikael Nielsen ,  Nikolaj Eusebius Jakobsen ,  Nikolaj Frogner Krusell

    IPC分类号： A61M5/00 ,  A61M5/24 ,  A61M5/20 ,  A61M5/315 ,  G06F19/00 ,  A61M5/31

    摘要： A medial assembly comprises a logging first unit adapted to be mounted on a drug delivery device second unit from a fully un-mounted to a fully mounted position along a path. The first unit comprises a switch operatable between an off- and an on-state when the first unit is mounted on the second unit, the switch being in the on-state when the first unit is mounted within a first distance from the fully mounted position, and in the off-state when the first unit is mounted outside the first distance from the fully mounted position, and a snap lock operatable from an initial state through an expanded state to a snap-in state when the first unit is mounted on the second unit, the snap lock being in the snap-in state when the first unit is mounted within a second distance from the fully mounted position, the second distance being shorter than the first distance. By this arrangement it is ensured that the switch will be in the on-state before the snap lock is in the snap-in state.

    TORSION SPRING FIXATION IN AUTOMATIC DRUG DELIVERY DEVICE
    118.
    发明申请
    TORSION SPRING FIXATION IN AUTOMATIC DRUG DELIVERY DEVICE 审中-公开

    公开(公告)号：US20190046734A1

    公开(公告)日：2019-02-14

    申请号：US15763491

    申请日：2016-09-29

    申请人： Novo Nordisk A/S

    发明人： Nikolaj Eusebius Jakobsen ,  Christian Peter Enggaard

    IPC分类号： A61M5/315 ,  A61M5/20

    摘要： A drug injection device (1) comprising a dose expelling mechanism for expelling drug from a reservoir through a reservoir outlet, the dose expelling mechanism comprising: a first component (40), a second component (10, 10′, 15′, 10″, 15″), and a torsion spring element (20) for inducing relative rotation between the first component (40) and the second component (10, 10′, 15′, 10″, 15″) to execute a dose expelling operation, the torsion spring element (20) extending along a longitudinal axis and comprising: a first spring end portion (22) being rotationally restrained with respect to the first component (40), and a second spring end portion (23) exhibiting an end portion inner diameter in a relaxed state of the torsion spring element (20), wherein the second spring end portion (23) is fitted over a spring receiving portion (11) of the second component (10, 10′, 15′, 10″, 15″), the spring receiving portion (11) having a transversal dimension which is larger than the end portion inner diameter, and the fitting of the second spring end portion (23) over the spring receiving portion (11) being configured to provide a sticking friction engagement between the two when the torsion spring element (20) is strained to exert a maximum in-use torque.

    State Changing Appliance for Drug Delivery Device
    119.
    发明申请
    State Changing Appliance for Drug Delivery Device 审中-公开

    公开(公告)号：US20190038841A1

    公开(公告)日：2019-02-07

    申请号：US16152444

    申请日：2018-10-05

    申请人： Novo Nordisk A/S

    发明人： Mads Schenstroem Stefansen

    IPC分类号： A61M5/315

    摘要： A system comprising a state changing appliance and a drug delivery device, the state changing appliance comprising first interface means for rotationally locking to a first exterior portion of the drug delivery device, second interface means for rotationally locking to a second exterior portion of the drug delivery device, the first exterior portion and the second exterior portion being angularly displaceable relative to one another from a first relative position to a second relative position, which second relative position defines a set dose to be expelled by the drug delivery device, and limiter means for limiting a relative angular displacement between the first interface means and the second interface means.

    GLP-1 derivatives and uses thereof
    120.
    发明授权
    GLP-1 derivatives and uses thereof 有权

    公开(公告)号：US10195255B2

    公开(公告)日：2019-02-05

    申请号：US14897738

    申请日：2014-06-19

    申请人： Novo Nordisk A/S

    发明人： Steffen Reedtz-Runge ,  Per Sauerberg ,  Jacob Kofoed ,  Ingrid Pettersson ,  Christian W. Tornoee

    IPC分类号： A61K47/54 ,  A61K47/56 ,  A61K47/60 ,  A61K38/26 ,  C07K14/605

    摘要： The invention relates to a derivative of a GLP-1 analogue, optionally C-terminally extended, which derivative comprises a first and a second protracting moiety in the form of a C20 or C22 diacid radical, a bis-amino branched linker, and a first and a second further linker each comprising an OEG-like linker element; wherein these elements are interconnected via amide bonds and attached to a Lys residue of the GLP-1 analogue. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.